EpiWatch is a startup company that has developed an AI/ML based continuous seizure monitor (CSM) app running on an Apple Watch platform. EpiWatch detects and alerts for tonic-clonic seizures associated with epilepsy. The proprietary algorithm collects biosignals from Apple Watch and utilizes a patented algorithm to detect and record seizure activity and send an alert to designated caregivers. With an estimated potential audience of nearly 4 million people with epilepsy (PWE) in the US and 65 million globally, EpiWatch will be launched initially in the US, with expansion into other markets.

EpiWatch has completed a multi-site clinical trial with very favorable results and is currently working toward FDA clearance. The abstract related to the trial, High Accuracy for Detecting Tonic Clonic seizures (TCSs) Using an Apple Watch Seizure Detector, was presented at the American Epilepsy Society Annual Meeting in December 2024.